Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial
Re:GEN Open · 2021
DOI: 10.1089/regen.2021.0018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Re:GEN Open, 2021. Verfasst von Javier F. Casiraghi und 4 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Purpose
To assess the effectiveness and tolerability of a new latanoprost 0.005% benzalkonium chloride (BAK)-free nanoemulsion.
Methods
A nonrandomized multicenter study was conducted between January 2017 and October 2017 in 15 ophthalmological clinics from Argentina. This study enrolled 113 patients with primary open angle glaucoma or pseudoexfoliative glaucoma, who had been under treatment with any BAK-preserved latanoprost ophthalmic solution 0.005% as monotherapy for at least 6 months, switch to administer latanoprost BAK-free nanoemulsion. Primary outcome was intraocular pressure (IOP) lowering efficacy at 4, 8, and 12 weeks after treatment switch. Secondary outcomes included clinical signs and symptoms of ocular surface damage (Ocular Surface Disease Index (OSDI), conjunctival hyperemia, Schirmer I test, tear film break-up time (BUT), corneal epithelial fluorescein staining, and tear meniscus height).
Results
In total, 103 patients (198 eyes) concluded the study. Mean IOP values between baseline and at week 12 were 14.63 (95% confidence interval (CI), 14.25 to 15.01) and 13.65 (95% CI, 13.32 to 13.98). After a 12 weeks of treatment switch, mean Ocular Surface Diseases Index score decreased by 11.53 units (95% CI, 15.18 to 7.88; p < 0.0001), and the number of eyes with conjunctival hyperemia decreased by 27.8% (95% CI, 17.93 to 37.64; p < 0.0001). Mean break-up time increased by 1.75 seconds (95% CI, 1.37 to 2.12; p < 0.0001) 12 weeks after treatment switch, and the number of eyes with corneal staining decreased by 19.7% (95% CI, 11.68 to 27.72; p < 0.0001).
Conclusions
The new nanoemulsion maintains the decreasing intraocular pressure effect, with significant improvements in signs and symptoms of ocular surface disease.
Zitieren
APA
Casiraghi, J. F., Grigera, D., Peyret, J. A., Papa, M. D., & Passerini, M. S. (2021). Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial. Re:GEN Open. https://doi.org/10.1089/regen.2021.0018
Vancouver
Casiraghi JF, Grigera D, Peyret JA, Papa MD, Passerini MS. Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial. Re:GEN Open. 2021. doi:10.1089/regen.2021.0018
BibTeX
@article{Casiraghi2021,
author = {Casiraghi, Javier F. and Grigera, Daniel and Peyret, J. Alejo and Papa, Melina del and Passerini, María Silvia},
title = {Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial},
journal = {Re:GEN Open},
year = {2021},
doi = {10.1089/regen.2021.0018}
}
EUVIMED